
Celltrion’s YUFLYMA (adalimumab-aaty) Receives FDA Interchangeable Designation as Biosimilar to Humira (adalimumab)
On April 14, 2025, Celltrion announced that it was granted interchangeable designation by FDA for its adalimumab-aaty (brand name YUFLYMA), a biosimilar to adalimumab (brand name Humira). Adalimumab-aaty is approved by FDA as a high-concentration (100mg…